Population Pharmacokinetic Estimation of Melphalan Exposure Predicts Disease Control and Toxicity After Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
Authors:
- Natalia Tijaro OvalleNONatalia Tijaro Ovalle
- Andrew LinALAndrew Lin
- Nancy Cruz SitnerNSNancy Cruz Sitner
- Ryan SchofieldRSRyan Schofield
- Brenden BreadyBBBrenden Bready
- Mithat GonenMGMithat Gonen
- A. Zara HerskovitsAHA. Zara Herskovits
- Ross S. FirestoneRFRoss S. Firestone
- Hamza HashmiHHHamza Hashmi
- Hani HassounHHHani Hassoun
- Malin HultcrantzMHMalin Hultcrantz
- Neha S. KordeNKNeha S. Korde
- 13 October 2026
- journal article
- Published by Elsevier in Transplantation and Cellular Therapy
Abstract
No abstract availableFunding Information
- National Cancer Institute
This publication has 23 references indexed in Scilit:
- Optimizing high dose melphalanBlood Reviews, 2023
- Determination of Busulfan and Melphalan in Plasma by Turbulent Flow Chromatography-Tandem Mass Spectrometry2023
- Early relapse within 18 months is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myelomaCancer, 2023
- Evaluation of Melphalan Exposure in Lymphoma Patients Undergoing BEAM and Autologous Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2022
- Population Pharmacokinetics of Melphalan in a Large Cohort of Autologous and Allogeneic Hematopoietic Cell Transplantation Recipients: Towards Individualized Dosing RegimensClinical Pharmacokinetics, 2021
- Budesonide Prophylaxis Reduces the Risk of Engraftment Syndrome After Autologous Hematopoietic Cell Transplantation in Multiple MyelomaClinical Lymphoma Myeloma and Leukemia, 2021
- Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular TherapyTransplantation and Cellular Therapy, 2020
- Successful Personalization of Propylene Glycol Free Melphalan (PGF-MEL) for Multiple Myeloma (MM) and AL Amyloidosis (AL) Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT) Using Pharmacokinetic (PK)-Directed DosingTransplantation and Cellular Therapy, 2020
- Population Pharmacokinetics and Optimal Sampling Strategy for Model-Based Precision Dosing of Melphalan in Patients Undergoing Hematopoietic Stem Cell TransplantationClinical Pharmacokinetics, 2017
- A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous TransplantationTransplantation and Cellular Therapy, 2015